EGFR and non-small cell lung carcinoma: For example, the use of liquid biopsy has now been implemented for several years for therapeutic purposes and the detection of resistance mechanisms in non-small cell lung cancer patients with EGFR mutations treated with anti-EGFR therapies [98].